Finance

Lists
Why is ZTS up 2.52%?
Dive Deeper
ZTS:NYSE
Zoetis Inc
$ 85.57
+2.52%
(+2.10) 1D
$ 85.80
+0.27% (+0.23)
After hours
Closed: 11-р сарын 18, 16:03:16 (GMT-5)  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ZTS...
Open
$ 82.15
High
$ 86.58
Low
$ 82.15
Mkt. cap
34.77 тэрбум
Avg. vol.
4.44 сая
Volume
320.00
Dividend
2.48%
Quarterly dividend
$ 0.53
Ex-dividend date
2026 оны 10-р сарын 30
P/E ratio
14.53
52-wk high
$ 132.49
52-wk low
$ 68.77
EPS
$ 5.89
Beta
0.67
Shares outstanding
406.32 сая
No. of employees
14 мян
Open
$ 82.15
High
$ 86.58
Low
$ 82.15
Mkt. cap
34.77 тэрбум
Avg. vol.
4.44 сая
Volume
320.00
Dividend
2.48%
Quarterly dividend
$ 0.53
Ex-dividend date
2026 оны 10-р сарын 30
P/E ratio
14.53
52-wk high
$ 132.49
52-wk low
$ 68.77
EPS
$ 5.89
Beta
0.67
Shares outstanding
406.32 сая
No. of employees
14 мян
News stories
From web sources and news partners
Profile
Zoetis Inc., headquartered in Parsippany, New Jersey, is the largest producer of medicine and vaccinations for pets and livestock worldwide. The company's products include antiparasitics, vaccines, products that relieve itch, anti-infectives, products that alleviate pain, animal health diagnostics, as well as hormones, cardiopulmonary, topical and oral hygiene therapeutics, central nervous system drugs, diuretics, antiemetic, euthanasia, and hepato-digestive products. The company has operations in over 50 countries. In 2025, 70% of the company's revenue came from products for pets and 29% of the company's revenues came from products for livestock. In 2025, 54% of the company's revenue came from customers in the United States. Of this revenue, 79% came from products for dogs and cats, 13% came from products for cattle, and 4% came from products for horses. In 2025, 46% of the company's revenue came from international customers. Of this revenue, 53% came from products for dogs and cats, 19% came from products for cattle, 9% came from products for swine, 7% came from products for poultry, and 3% came from products for horses. Wikipedia
About Zoetis Inc
CEOKristin C. Peck
Employees14.5 мян
Founded1952
HeadquartersParsippany-Troy Hills, Нью Жерси, Америкийн Нэгдсэн Улс
SectorHealth Care
IndustryPharmaceutical industry
Websitezoetis.com
Analyst ratings
Based on 11 analysts giving stock ratings to ZTS in the past 3 months
Buy
Buy
3
Hold
8
Sell
0
12-month forecast
Based on 11 Wall Street analysts offering 12 month price targets for ZTS in the last 3 months.
Highest
Current $ 85.57
$ 115.00 (+34.39%)
Average
$ 87.00 (+1.67%)
Lowest
$ 74.00 (-13.52%)
Analyst
Recommendation
Action
Price target
Projected
Date
Glen Santangelo
Barclays
Hold
Maintained
$ 85.00
-0.7%
11/17/2026
David Westenberg
Piper Sandler
Hold
Maintained
$ 80.00
-6.5%
11/09/2026
Andrea Alfonso
UBS
Hold
Maintained
$ 85.00
-0.7%
11/06/2026
Scott Schoenhaus
KeyBanc
Hold
Maintained
-
-
11/06/2026
Jonathan Block
Stifel Nicolaus
Hold
Maintained
$ 85.00
-0.7%
11/05/2026
Erin Wright
Morgan Stanley
Buy
Maintained
$ 82.00
-4.2%
10/30/2026
Keith Devas
Jefferies
Hold
Downgraded
$ 83.00
-3%
10/20/2026
Chris Schott
J.P. Morgan
Buy
Maintained
$ 115.00
+34.4%
10/16/2026
Matthew Dellatorre
Goldman Sachs
Hold
Initiated
$ 74.00
-13.5%
10/16/2026
Daniel Clark
Leerink Partners
Hold
Reiterated
-
-
10/01/2026
Steve Scala
TD Cowen
Buy
Reiterated
$ 94.00
+9.9%
08/25/2026
Daniel Grosslight
Citi
Buy
Maintained
$ 96.00
+12.2%
08/11/2026
Ryan Daniels
William Blair
Hold
Downgraded
-
-
08/06/2026
Brandon Vazquez
William Blair
Hold
Downgraded
-
-
08/08/2026
Michael Ryskin
Bank of America Securities
Hold
Maintained
-
-
07/28/2026
Sidharth Sahoo
HSBC
Buy
Maintained
$ 95.00
+11%
07/06/2026
Jasper Hellweg
Argus Research
Hold
Downgraded
-
-
05/26/2026
Thomas DeBourcy
Nephron
Hold
Downgraded
$ 131.00
+53.1%
03/05/2026
Mark Massaro
BTIG
Buy
Reiterated
$ 160.00
+87%
02/26/2026
Last report
2026 оны 11-р сарын 5
Fiscal period
Q3 2026
$ 1.75 / $ 1.51
+15.81%beat
Revenue / Est. (USD)
2.39 тэрбум / 2.30 тэрбум
+3.88%beat
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025 оны 12-р сар
2026 оны 3-р сар
2026 оны 6-р сар
2026 оны 9-р сар
Revenue
2.39 тэрбум
2.26 тэрбум
2.47 тэрбум
2.39 тэрбум
Cost of goods sold
711.00 сая
640.00 сая
670.00 сая
696.00 сая
Cost of revenue
711.00 сая
640.00 сая
670.00 сая
696.00 сая
Research and development expenses
199.00 сая
180.00 сая
173.00 сая
174.00 сая
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
618.00 сая
584.00 сая
589.00 сая
577.00 сая
Operating expense
848.00 сая
795.00 сая
793.00 сая
782.00 сая
Total operating expenses
1.56 тэрбум
1.44 тэрбум
1.46 тэрбум
1.48 тэрбум
Operating income
828.00 сая
827.00 сая
1.00 тэрбум
913.00 сая
Other non operating income
-6.00 сая
-1.00 сая
-2.00 сая
-3.00 сая
EBT including unusual items
761.00 сая
758.00 сая
866.00 сая
729.00 сая
EBT excluding unusual items
780.00 сая
779.00 сая
948.00 сая
857.00 сая
Income tax expense
158.00 сая
157.00 сая
175.00 сая
138.00 сая
Effective tax rate
20.76%
20.71%
20.21%
18.93%
Other operating expenses
-
-
-
-
Net income
603.00 сая
601.00 сая
691.00 сая
591.00 сая
Net profit margin
25.26%
26.57%
28.00%
24.72%
Earnings per share
1.48
1.53
1.87
1.75
Interest and investment income
25.00 сая
21.00 сая
16.00 сая
17.00 сая
Interest expense
-57.00 сая
-62.00 сая
-61.00 сая
-62.00 сая
Net interest expenses
-32.00 сая
-41.00 сая
-45.00 сая
-45.00 сая
Depreciation and amortization charges
-
-
-
-
EBITDA
903.00 сая
946.00 сая
1.12 тэрбум
1.03 тэрбум
Gain or loss from assets sale
-
-6.00 сая
-1.00 сая
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
Google аппс